The IFM team sets up a three-peat as No­var­tis funds cGAS/STING pro­gram — with $840M op­tion to buy

First there was Bris­tol-My­ers Squibb’s $2.3 bil­lion-plus deal with IFM — $300 mil­lion up front — to grab pre­clin­i­cal small mol­e­cules to ac­ti­vate NL­RP3 and STING in fight­ing can­cer. That was 2 years ago.

Then No­var­tis’ trans­la­tion­al team un­der Jay Brad­ner jumped in and grabbed the flip side of that coin, pay­ing the IFM crew $310 mil­lion up­front in a $1.6 bil­lion bid to demon­strate what NL­RP3 can do as an an­ti-in­flam­ma­to­ry. That work — held in a sub­sidiary called IFM Tre — had just be­gun hu­man stud­ies 5 months ago.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.